**IPNA PHARMACHEM LIMITED** 

CIN :- U24100GJ2011PTC066400 GSTN :- 24AADCD9404F1ZY

Date: 14th November, 2022

To, BSE Limited Phiroze Jeejeebhoy Tower, Dalal Street, Mumbai – 400 001

Dear Sir / Madam,

# Sub: Submission of Unaudited Financial Results for the Half Year ended on 30<sup>th</sup> September, 2022 along with Limited Review Report

#### Ref: Security Id: DPL / Code: 543594

In reference to captioned subject and pursuant to Regulation 33(3) (d) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we are hereby submitting the Unaudited Financial Results for the Half Year ended on 30<sup>th</sup> September, 2022 along with Limited Review Report.

Please take note of the same and oblige.

For, Dipna Pharmachem Limited



### **DIPNA PHARMACHEM LIMITED**

Keyur Shah Managing Director DIN: 03167258

Office Address:-A-211,SiddhiVinayak Tower, B/H DCP Office, Off. S.G.Highway, GodownAddress :-C-124, Sagar Estate, Nr Relief Hotel, S.G. Road, O79-66170806 / 07

dharachem99@yahoo.in / info@dipnapharmachem.com

|                 |  | ( Martha Barta I |                              |            | (Rs. In Lakhs Except EPS                                 |
|-----------------|--|------------------|------------------------------|------------|--|
| Sr. no          | Particulars  | 30.09.2022       | 6 Months Ended<br>31.03.2022 | 30.09.2021 | Year ended<br>31.03.2022                                 |
|                 |  | Unaudited        | Audited                      | Unaudited  | Audited  |
|                 | Laura Garage Competing   | Ondudited        | nuuiteu                      | ondutieu   | Auditeu  |
| 1               | Income from Operations   |                  |                              |            |  |
|                 | Net Sales /Income from Operations  | 4860.37          | 4350.54                      | 2925.01    | 7275.5   |
|                 | Other Operating Income   | 0.00             | 0.89                         | 0.15       | 1.0-   |
|                 | Total Income from Operations (Net)   | 4860.37          | 4351.43                      | 2925.16    | 7276.5   |
| 2               | Expenditure  |                  |                              |            |  |
|                 | Cost of material consumed  | 0.00             | 0.00                         | 0.00       | 0.0  |
|                 | Purchase of stock in trade   | 5585.19          | 3786.85                      | 2979.82    | 6766.67  |
|                 | Changes in Inventories of finished goods, work-in-progress   |                  |                              |            |  |
|                 | and stock in trade   | -934.95          | 293.40                       | -204.25    | 89.1   |
|                 | Employees cost   | 18.30            | 29.18                        | 24.36      | 53.5   |
|                 | Depreciation   | 0.47             | 0.31                         | 0.31       | 0.6  |
|                 | Finance Cost   | 44.75            | 30.42                        | 32.52      | 62.9   |
|                 | Power and Fuel   | 0.22             | 0.06                         | 0.04       | 0.1  |
|                 | Other Expense  | 101.16           | 97.29                        | 48.84      | 146.13   |
|                 | Total Expenses   | 4815.13          | 4237.51                      | 2881.65    | 7119.1   |
| 4               | Profit from Operations before Exceptional Items Tax  | 45.23            | 113.92                       | 43.51      | 157.4  |
| 5               | Exceptional Items  |                  | 0.00                         | 0.00       | 0.00   |
| 6               | Profit before Tax  | 45.23            | 113.92                       | 43.51      | 157.43   |
|                 | Current Tax  | 12.00            | 29.74                        | 11.00      | 40.7   |
|                 | Deferred Tax   | 0.00             | 0.00                         | 0.00       | 0.0  |
| 7               | Total Tax Expenses   | 12.00            | 29.74                        | 11.00      | 40.74  |
| 8               | Net Profit for the Period From Countinuing Operations  | 33.23            | 84.18                        | 32.51      | 116.6  |
| 9               | Details of Equity Shares   |                  |                              |            |  |
|                 | Paid up Equity Share Capital   | 1197.00          | 3.50                         | 3.50       | 3.5  |
|                 | Face Value of Equity Share Capital   | 1197.00          | 3.50                         | 3.50       | 3.5  |
|                 | Reserves   | 1180.85          | 84.17                        | 86.18      | 170.3  |
| 10              | Earning Per Share  |                  |                              |            |  |
| 10              | Basic Earning per Share  | 0.28             | 240.51                       | 92.88      | 333.39   |
|                 | Diluted Earning per Share  | 0.28             | 240.51                       | 92.88      | 333.39   |
|                 | ted Financial Statement has been reviewed by the Audit Committee   |                  |                              |            | held on 14th November,                                   |
| anies Act, 2013 |  |                  |                              |            |  |
| ng              | ng to Segment wise reporting is not applicable as the Company opera-<br>ing to previous periods have been regrouped, re-classified and resta |                  | sarv                         |            |  |
| : Ahmedabad     |  |                  | HANN Y                       |            | IA PHARMACHEM LIMITEI<br>KEYUR SHAI<br>MANAGING DIRECTOI |

|       | CIN: U24100GJ20<br>REGD. OFFICE: A-211 , Siddhi Vinayk Tower, B/I<br>STATEMENT OF ASSETS AND LIABILITIES FOR TH | h DCP Office, Makarba, Ahme |                                  |
|-------|---|-----------------------------|----------------------------------|
| -     |   |                             | (` In Lakh                       |
|       | Particulars   | As at 30.09.2022            | As at 31.03.2022                 |
|       | JITY AND LIABILITIES  |                             |                                  |
| 1 Equ |   | 1107.00                     | 2                                |
|       | a) Equity Share Capital<br>b) Other Equity  | 1197.00<br>1180.85          | 3.<br>170.                       |
|       | Sub-total - Equity  | 2377.85                     | 173.8                            |
|       | bilities  |                             |                                  |
|       | n-Current Liabilities   |                             |                                  |
| (     | a) Financial Liabilities  | 0.00                        | 0.0                              |
|       | (i) Borowings   | 347.61<br>0.00              | 332.                             |
| 6     | (ii) Trade Payables<br>iii) Other Financial Liabilities (other than those                                       | 0.00                        | 0.                               |
|       | cified in ithem (b), to be specified)   | 0.00                        | 0.                               |
|       | b) Provisions   | 0.00                        | 0.                               |
| (     | c) Deferred Tax Liabilities (Net)   | 0.00                        | 0.                               |
| (     | d) Other Non-Current Liabilities  | 0.00                        | 0.                               |
|       | Sub-total - Non Current Liabilities   | 347.61                      | 332.                             |
| Cur   | rent liabilities  |                             |                                  |
|       | a) Financial Liabilities  | 0.00                        | 0.                               |
|       | (i) Borowings   | 450.89                      | 686.                             |
|       | (ii) Trade Payables   |                             |                                  |
|       | tal outstanding dues of micro enterprises and small   | 917.81                      | 386.                             |
|       | erprises  | 2070.00                     | 1016                             |
|       | otal outstanding dues of creditors other than micro<br>erprises and small enterprises                           | 2978.99                     | 1916.                            |
| ente  | (iii) Other Financial Liabilities (Current Maturities   |                             |                                  |
| 1     |   |                             |                                  |
|       | of Long term Debt)  | 0.00                        | 0.                               |
|       | b) Other Current Liabilities  | 8.83                        | 86.                              |
|       | c) Provisions   | 52.25<br>0.00               | 40.                              |
| - (0  | d) Current Tax Liabilities (Net)<br>Sub-total - Current Liabilities   | 4408.77                     | 0.                               |
|       | TOTAL - EQUITY AND LIABILITIES  | 7134.23                     | 3622.9                           |
| ASS   |   |                             |                                  |
|       | -Current Assets   |                             |                                  |
|       | a) Property, Plant and Equipment  | 4.62                        | 4.:                              |
|       | b) Capital work-in-progress<br>c) Investment Property   | 0.00                        | 0.0                              |
|       | d) Goodwill   |                             | 0.0                              |
|       | e) Other Intangible Assets  |                             | 0.0                              |
| (f    | ) Intangible Assets under Development   |                             | 0.0                              |
|       | g) Biological Assets other than Bearer Plants   |                             | 0.0                              |
| (0    | (i) Investments   |                             | 0.0                              |
|       | (ii) Trade Receivables  |                             | 0.0                              |
|       | (iii) Loans   |                             | 0.0                              |
| (0    | I) Deferred Tax Assets (net)  |                             | 0.0                              |
| (6    | e) Other Non-Current Assets   |                             | 0.0                              |
| -     | Sub-total - Non-Current Assets  | 4.62                        | 4.1                              |
|       | n Inventories   | 1565.30                     | 630.3                            |
| 1     | ) Financial Assets  | 0.00                        | 0.0                              |
|       | (i) Investment  | 0.00                        | 0.0                              |
|       | (ii) Trade Receivables  | 2710.93                     | 2697.4                           |
| Ι.    | (iii) Cash and Cash Equivalents   | 513.02                      | 20.5                             |
|       | (iv) Bank Balances other than (iii) above   | 0.00                        | 0.0                              |
| 6     | (v) Loans   | 1668.95<br>0.00             | 1.0                              |
|       | ri) Others (to be specified)<br>c) Current Tax Assets (Net)   | 0.00                        | 0.0                              |
|       | I) Other Current Assets   | 671.41                      | 269.1                            |
|       | Sub-total - Current Assets  | 7129.61                     | 3618.8                           |
|       | TOTAL - ASSETS  | 7134.23                     | 3622.9                           |
|       |   | AMACA                       |                                  |
|       |   | R FOR DI                    | PNA PHARMACHEM LIMITE            |
|       |   | 5/ 12/                      | Sent                             |
|       | 1   |                             | KEYUR SHA                        |
|       |   |                             |                                  |
|       | hmedabad<br>4/11/2022   | A IS                        | MANAGING DIRECTO<br>DIN: 0316725 |

#### DIPNA PHARMACHEM LIMITED CIN: U24100GJ2011PLC066400

#### REGD. OFFICE: A-211 , Siddhi Vinayk Tower, B/h DCP Office, Makarba, Ahmedabad-380051

#### CASH FLOW STATEMENT FOR THE HALF YEAR ENDED 30TH SEPTEMBER, 2022

|   |                  | (`In Lakh         |
|---|------------------|-------------------|
| Particulars   | AS ON 30-09-2022 | AS ON 31-03-2022  |
| A. CASH FLOW FROM OPERATING ACTIVITIES                    |                  |                   |
| Profit Before Tax   | 45.24            | 157.4             |
| Adjustment For :  |                  | 2077              |
| Depreciation of property, plant & equipment               | 0.47             | 0.0               |
| Finance Cost  | 44.75            | 62.9              |
| nterest Income classified as Investing Cash Flows         | 11.75            | (0.8              |
| Other Comprehensive Expense                               | 0.00             | 0.0               |
| Profit) / Loss on sale of property, plant & equipment     | 0.00             | 0.                |
|   | 90.45            |                   |
| Operating Profit before working capital changes           | 90.45            | 220.1             |
| Adjustment For :  | (004.05)         | 22                |
| a) (Increase)/Decrease in Inventories                     | (934.95)         | 89.               |
| b) (Increase)/Decrease in Trade Receivables               | (13.44)          | (1202.7           |
| b) (Increase)/Decrease in Current Assets                  | (402.30)         | (34.4             |
| c) (Increase)/Decrease in Non-Current Financial Assets    | 0.00             | 0.                |
| d) Increase /(Decrease) in Long Term Provisions           | 0.00             | 0.0               |
| e) Increase /(Decrease) in Long Term Borrowings           | 15.00            | (35.2             |
| f) Increase /(Decrease) in Short Term Borrowings          | (235.39)         | (188.5            |
| g) Increase /(Decrease) in Other Current Liabilites       | (78.14)          | 86.               |
| h) Increase /(Decrease) in Short Term Provisions          | 12.00            | 39.               |
| i) Increase /(Decrease) in Trade Payable                  | 1593.80          | 1125.             |
| ASH GENERATED FROM OPERATIONS                             | 47.03            | 99.0              |
| ess :(a) Income Tax Paid                                  | 12.00            | 40.               |
| NET CASH INFLOW FROM OPERATING ACTIVITIES (A)             | 35.03            | 58.3              |
| 3. CASH FLOW FROM INVESTING ACTIVITIES                    | 00100            | 001               |
| a) Purchase of Fixed Assets                               | (0.97)           | (0.6              |
| b) Sale of Fixed Assets                                   | (0.57)           | 0.0               |
| c) Investment   |                  | 0.0               |
| d) Interest Income  |                  | 0.0               |
|   | (0.97)           | 0.1               |
| NET CASH INFLOW / (OUTFLOW) FROM INVESTING ACTIVITIES (B) | (0.97)           | 0.1               |
| C. CASH FLOW FROM FINANCING ACTIVITIES                    |                  |                   |
| a) Proceeds/( Repayment) from Borrowings                  |                  | 0.0               |
| b) Subsidy Received                                       |                  | 0.0               |
| c) Loans granted  | (1667.91)        |                   |
| d) Proceeds from Issue of Share Capital                   | 2170.76          | 0.0               |
| e) Interest Paid  | (44.75)          | (62.9-            |
| NET CASH INFLOW/ (OUTFLOW) IN FINANCING ACTIVITIES (C)    | 458.10           | (62.94            |
| NET INCREASE IN CASH & CASH EQUIVALENTS (A+B+C)           | 492.16           | (4.4)             |
| PENING BALANCE – CASH & CASH EQUIVALENT                   | 20.87            | 25.3              |
| LOSING BALANCE - CASH & CASH EQUIVALENT                   | 513.02           | 20.8              |
| 1   | MACA FOR DIPNA   | PHARMACHEM LIMITE |
|   | MACA             | 1                 |
|   | 1311             | Jour              |
|   |                  |                   |
|   |                  | KEYUR SHA         |
| Place : Ahmedabad   | 1311             | MANAGING DIRECTO  |
|   | 151              | DIN: 0316725      |
| ate : 14/11/2022  |                  | DIN:031072        |

## <u>B S JAIN & CO</u>

CHARTERED ACCOUNTANTS

701/B, Mahalay Complex, Opp. Hotel President, C.G. ROAD, Navrangpura, Ahmedabad – 380009PH (0):- 079-35604942, (M): - +91-7567677007Email ID: - bsjainandco@gmail.com

To,

The Board of Directors

Dipna Pharmachem Limited

- 1. We have reviewed the accompanying Statement of Unaudited Standalone Financial Results of **Dipna Pharmachem Limited** (the "Company") for the half year ended **September 30**, **2022** and the relevant notes thereon (the "Statement"). The Statement has been prepared by the Company pursuant to Regulation 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 (The "Listing Regulations, 2015"), which has been initialled by us for identification purposes. The Statement is the responsibility of the Company's management and has been approved by the Board of Directors. Our responsibility is to issue a report on the Statement based on our review.
- 2. This Statement, which is the responsibility of the Management and approved by the Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standard 34 "Interim Financial Reporting" (Ind AS 34), prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other accounting principles generally accepted in India. Our responsibility is to express a conclusion on the Statement based on our review.
- 3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India (ICAI). A review of interim financial information consists of making inquiries, primarily of Company's personnel responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing specified under Section 143(10) of the Companies Act, 2013 and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.
- 4. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying Statement has not been prepared in all material respects in accordance with Ind AS and other recognised accounting practices and policies and has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI Listing Regulations, 2015, as amended, including the manner in which it is to be disclosed, or that it contains any material misstatement.

Place: Ahmedabad Date: November 14, 2022

